#32026D0575Council Decision (EU) 2026/575 on the EU position at the 69th CND session regarding scheduling of three new psychoactive substances
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This Council Decision establishes the official EU position for the 69th session of the UN Commission on Narcotic Drugs (Vienna, 9-13 March 2026). The EU supports adding three new synthetic substances to international drug control treaties based on WHO recommendations. N-pyrrolidino isotonitazene (Isotonitazepyne) and N-desethyl etonitazene are to be placed in Schedule I of the 1961 Single Convention on Narcotic Drugs, while MDMB-FUBINACA is to be added to Schedule II of the 1971 Convention on Psychotropic Substances. These nitazene opioids and synthetic cannabinoid have been detected in multiple EU Member States, linked to deaths and poisonings, and are already under EU monitoring.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- EU Member States must support adding N-pyrrolidino isotonitazene to Schedule I of the 1961 Single Convention
- EU Member States must support adding N-desethyl etonitazene to Schedule I of the 1961 Single Convention
- EU Member States must support adding MDMB-FUBINACA to Schedule II of the 1971 Psychotropic Substances Convention
+ 2 more changes with Pro
Obligations
What this law requires
EU Member States that are members of the Commission on Narcotic Drugs must vote to support adding N-pyrrolidino isotonitazene to Schedule I of the 1961 Single Convention on Narcotic Drugs at the 69th CND session (9-13 March 2026)
EU Member States that are members of the Commission on Narcotic Drugs must vote to support adding N-desethyl etonitazene to Schedule I of the 1961 Single Convention on Narcotic Drugs at the 69th CND session (9-13 March 2026)
EU Member States that are members of the Commission on Narcotic Drugs must vote to support adding MDMB-FUBINACA to Schedule II of the 1971 Convention on Psychotropic Substances at the 69th CND session (9-13 March 2026)
Member States must ensure that scheduling decisions adopted by the CND are incorporated into their implementation of Council Framework Decision 2004/757/JHA regarding drug control
The European Union Drugs Agency (EUDA) must continue intensive monitoring of N-pyrrolidino isotonitazene, N-desethyl etonitazene, and MDMB-FUBINACA as new psychoactive substances under Regulation (EU) 2023/1322